Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.

Oliva E, Pinheiro NF, Heney NM, Kaufman DS, Shipley WU, Gurski C, Spicer B, Paner GP, Gown AM, Amin MB.

Hum Pathol. 2013 May;44(5):860-6. doi: 10.1016/j.humpath.2012.08.011. Epub 2012 Nov 27.

PMID:
23199526
2.

Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.

Aron M, Luthringer DJ, McKenney JK, Hansel DE, Westfall DE, Parakh R, Mohanty SK, Balzer B, Amin MB.

Am J Surg Pathol. 2013 Dec;37(12):1815-23. doi: 10.1097/PAS.0000000000000114.

PMID:
24225842
4.

The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.

Jung S, Wu C, Eslami Z, Tanguay S, Aprikian A, Kassouf W, Brimo F.

Ann Diagn Pathol. 2014 Feb;18(1):27-32. doi: 10.1016/j.anndiagpath.2013.10.006. Epub 2013 Oct 31.

PMID:
24321464
5.

Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.

Mallofré C, Castillo M, Morente V, Solé M.

Mod Pathol. 2003 Mar;16(3):187-91.

6.

Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.

Edgecombe A, Nguyen BN, Djordjevic B, Belanger EC, Mai KT.

Appl Immunohistochem Mol Morphol. 2012 May;20(3):264-71. doi: 10.1097/PAI.0b013e3182351ed3.

PMID:
22498670
7.

[Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].

Xiao L, Wang CF, Zhu XZ, Yin YL, Chen Y, Lu C, Yu B.

Zhonghua Bing Li Xue Za Zhi. 2011 May;40(5):319-23. Chinese.

PMID:
21756826
8.

Atypia in inverted urothelial papillomas: pathology and prognostic significance.

Broussard JN, Tan PH, Epstein JI.

Hum Pathol. 2004 Dec;35(12):1499-504.

PMID:
15619209
9.
10.

Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.

Jones TD, Zhang S, Lopez-Beltran A, Eble JN, Sung MT, MacLennan GT, Montironi R, Tan PH, Zheng S, Baldridge LA, Cheng L.

Am J Surg Pathol. 2007 Dec;31(12):1861-7.

PMID:
18043040
12.

p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.

Yin M, Bastacky S, Parwani AV, McHale T, Dhir R.

Hum Pathol. 2008 Apr;39(4):527-35. doi: 10.1016/j.humpath.2007.08.005. Epub 2008 Jan 30.

PMID:
18234280
13.

Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium.

Yin H, He Q, Li T, Leong AS.

Appl Immunohistochem Mol Morphol. 2006 Sep;14(3):260-5.

PMID:
16932015
14.

Cytokeratin 20 as an objective marker of urothelial dysplasia.

Harnden P, Eardley I, Joyce AD, Southgate J.

Br J Urol. 1996 Dec;78(6):870-5.

PMID:
9014711
15.

Expression of CD44V2 in transitional cell carcinoma of the urinary bladder and in urine.

Müller M, Heicappell R, Habermann F, Kaufmann M, Steiner U, Miller K.

Urol Res. 1997;25(3):187-92.

PMID:
9228671
16.
17.

Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.

Guo CC, Fine SW, Epstein JI.

Am J Surg Pathol. 2006 Jul;30(7):883-91.

PMID:
16819332
18.

CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.

Fichtenbaum EJ, Marsh WL Jr, Zynger DL.

Am J Clin Pathol. 2012 Aug;138(2):190-7. doi: 10.1309/AJCP5ZC4GQVNWTYR.

PMID:
22904129
19.
20.

Evaluation of double immunocytochemical staining for CK20 and P53 as a potential adjunct to cytology for urothelial cancer diagnosis.

Lenos M, Katafigiotis I, Vrettou K, Papaioannou D, Malta F, Trigka EA, Sousouris S, Constantinides C, Mikou P.

Cytopathology. 2017 Apr;28(2):96-102. doi: 10.1111/cyt.12386. Epub 2016 Nov 18.

PMID:
27859848

Supplemental Content

Support Center